Mylan (NSDQ:MYL) said on Monday that it is undergoing an antitrust probe by the Federal Trade Commission into the company’s commercial practices regarding its EpiPen device.
The Canonsburg, Pa.-based company reportedly responded to the allegations that it improperly fought off competition, saying “any suggestion that Mylan took any inappropriate or unlawful actions to prevent generic competition is without merit.”
Get the full story at our sister site, Drug Delivery Business News.
The post Mylan hit with antitrust lawsuit over EpiPen device appeared first on MassDevice.